Amin M. Alousi,on behalf of the Blood and Marrow Transplant Clinical Trials Network,Daniel J. Weisdorf,on behalf of the Blood and Marrow Transplant Clinical Trials Network,Brent R. Logan,on behalf of the Blood and Marrow Transplant Clinical Trials Network,Javier Bolaños-Meade,on behalf of the Blood and Marrow Transplant Clinical Trials Network,Shelly Carter,on behalf of the Blood and Marrow Transplant Clinical Trials Network,Nancy DiFronzo,on behalf of the Blood and Marrow Transplant Clinical Trials Network,Marcelo Pasquini,on behalf of the Blood and Marrow Transplant Clinical Trials Network,Steven C. Goldstein,on behalf of the Blood and Marrow Transplant Clinical Trials Network,Vincent T. Ho,on behalf of the Blood and Marrow Transplant Clinical Trials Network,Brandon Hayes-Lattin,on behalf of the Blood and Marrow Transplant Clinical Trials Network,John R. Wingard,on behalf of the Blood and Marrow Transplant Clinical Trials Network,Mary M. Horowitz,on behalf of the Blood and Marrow Transplant Clinical Trials Network,John E. Levine,on behalf of the Blood and Marrow Transplant Clinical Trials Network

View Articletitled, Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
Brief Report

Prashant Kapoor,Shaji Kumar,Rafael Fonseca,Martha Q. Lacy,Thomas E. Witzig,Suzanne R. Hayman,Angela Dispenzieri,Francis Buadi,P. Leif Bergsagel,Morie A. Gertz,Robert J. Dalton,Joseph R. Mikhael,David Dingli,Craig B. Reeder,John A. Lust,Stephen J. Russell,Vivek Roy,Steven R. Zeldenrust,A. Keith Stewart,Robert A. Kyle,Philip R. Greipp,S. Vincent Rajkumar

View Articletitled, Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
Brief Report

Donna Reece,Kevin W. Song,Tommy Fu,Birgitte Roland,Hong Chang,Douglas E. Horsman,Adnan Mansoor,Christine Chen,Esther Masih-Khan,Young Trieu,Helene Bruyere,Douglas A. Stewart,Nizar J. Bahlis

View Articletitled, Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

GENE THERAPY

Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector

Ali Ramezani,Robert G. Hawley

View Articletitled, Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector

Issue Archive

Table of Contents

INSIDE BLOOD

REVIEW ARTICLES

CLINICAL TRIALS AND OBSERVATIONS

Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network Clinical Trials & Observations

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone Brief Report

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13 Brief Report

GENE THERAPY

IMMUNOBIOLOGY

Type 17 CD8+ T cells display enhanced antitumor immunity Brief Report

LYMPHOID NEOPLASIA

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia Brief Report

MYELOID NEOPLASIA

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells Brief Report

PLATELETS AND THROMBOPOIESIS

Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function Brief Report

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

TRANSPLANTATION

Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease Brief Report

VASCULAR BIOLOGY

CORRESPONDENCE

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network
Clinical Trials & Observations

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
Brief Report

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
Brief Report

Type 17 CD8⁺ T cells display enhanced antitumor immunity
Brief Report

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia
Brief Report

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells
Brief Report

Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function
Brief Report

Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease
Brief Report